| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 9.13 | -0.10 (-1.08%) | 4.79 - 9.39 | 32.7 million (Above Avg) |
Market data as of 4:00PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | 9.25 |
|---|---|
| Previous Close | 9.23 |
| Day's Range | 9.10 - 9.34 |
| Market Cap | 12.3B |
| Avg Volume (10 Day) | 29.3M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -3.23 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System
PR Newswire - Wednesday 05/22/2013 12:20 PM ET
Boston Scientific Reports Lotus™ Valve System Met Primary Performance Endpoint in REPRISE II Trial
PR Newswire - Wednesday 05/22/2013 10:41 AM ET
Boston Scientific Promus PREMIER™ And SYNERGY™ Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data
PR Newswire - Wednesday 05/22/2013 9:13 AM ET
Boston Scientific Long Term Data Demonstrate Bronchial Thermoplasty Treatment Benefits Persist Out to Five Years in Patients with Severe Asthma
PR Newswire - Tuesday 05/21/2013 11:46 AM ET
OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings
PR Newswire - Tuesday 05/21/2013 5:02 AM ET
Boston Scientific Presents Clinical Data at Digestive Disease Week®
PR Newswire - Friday 05/17/2013 9:01 AM ET
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
PR Newswire - Friday 05/17/2013 3:01 AM ET
First Patient Enrolled In Boston Scientific Randomized Study Comparing WallFlex® Biliary RX Stent To Absence Of Biliary Drainage In Patients With Pancreatic Or Periampullary Cancers
PR Newswire - Wednesday 05/15/2013 12:16 PM ET
| BSX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -5.53% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.65 | |
| LT Debt/Equity | 0.65 | |
| Earnings Yield | -- | |
| Price/Sales | 1.74 |
| Company | Last | Change |
|---|---|---|
| St. Jude Medical Inc | 45.70 | -2.31% |
| Zimmer Holdings Inc | 79.86 | -1.42% |
| Smith & Nephew PLC | 59.26 | -0.80% |
| Varian Medical Systems Inc | 68.43 | -2.07% |
| Edwards Lifesciences Corp | 64.30 | -2.58% |
Data is delayed by at least 15 min.